NASDAQ:RIGL

Rigel Pharmaceuticals Competitors

$3.58
-0.20 (-5.29 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.53
Now: $3.58
$3.79
50-Day Range
$3.09
MA: $3.75
$4.47
52-Week Range
$1.45
Now: $3.58
$5.50
Volume2.98 million shs
Average Volume3.90 million shs
Market Capitalization$609.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48

Competitors

Rigel Pharmaceuticals (NASDAQ:RIGL) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying RIGL stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Rigel Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Rigel Pharmaceuticals (NASDAQ:RIGL) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Institutional and Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rigel Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.27$-66,890,000.00($0.40)-8.95
Amgen$23.36 billion6.30$7.84 billion$14.8217.25

Amgen has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Rigel Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Amgen091402.61

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, indicating a potential upside of 132.77%. Amgen has a consensus target price of $261.0476, indicating a potential upside of 2.09%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Rigel Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Amgen29.42%95.55%15.52%

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Summary

Amgen beats Rigel Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Institutional and Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rigel Pharmaceuticals and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.27$-66,890,000.00($0.40)-8.95
Gilead Sciences$22.45 billion3.75$5.39 billion$6.1410.89

Gilead Sciences has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Rigel Pharmaceuticals and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Gilead Sciences191302.52

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, indicating a potential upside of 132.77%. Gilead Sciences has a consensus target price of $97.92, indicating a potential upside of 46.43%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than Gilead Sciences.

Profitability

This table compares Rigel Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Gilead Sciences5.48%37.77%12.76%

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Rigel Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Profitability

This table compares Rigel Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a summary of recent ratings and price targets for Rigel Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Vertex Pharmaceuticals042112.88

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, indicating a potential upside of 132.77%. Vertex Pharmaceuticals has a consensus target price of $293.1250, indicating a potential upside of 33.61%. Given Rigel Pharmaceuticals' higher probable upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Institutional and Insider Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Rigel Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.27$-66,890,000.00($0.40)-8.95
Vertex Pharmaceuticals$4.16 billion13.64$1.18 billion$4.2951.14

Vertex Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Rigel Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Regeneron Pharmaceuticals and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Regeneron Pharmaceuticals and Rigel Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Rigel Pharmaceuticals01302.75

Regeneron Pharmaceuticals currently has a consensus price target of $646.2609, indicating a potential upside of 28.58%. Rigel Pharmaceuticals has a consensus price target of $8.3333, indicating a potential upside of 132.77%. Given Rigel Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Rigel Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Rigel Pharmaceuticals$59.29 million10.27$-66,890,000.00($0.40)-8.95

Regeneron Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Rigel Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Biogen and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Biogen and Rigel Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Rigel Pharmaceuticals01302.75

Biogen currently has a consensus price target of $303.5862, indicating a potential upside of 12.31%. Rigel Pharmaceuticals has a consensus price target of $8.3333, indicating a potential upside of 132.77%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Biogen.

Institutional & Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Biogen and Rigel Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.86$5.89 billion$33.578.05
Rigel Pharmaceuticals$59.29 million10.27$-66,890,000.00($0.40)-8.95

Biogen has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Summary

Biogen beats Rigel Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Alexion Pharmaceuticals and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Alexion Pharmaceuticals and Rigel Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017512.30
Rigel Pharmaceuticals01302.75

Alexion Pharmaceuticals currently has a consensus price target of $153.8636, indicating a potential downside of 6.00%. Rigel Pharmaceuticals has a consensus price target of $8.3333, indicating a potential upside of 132.77%. Given Rigel Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Rigel Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.21$2.40 billion$9.7416.80
Rigel Pharmaceuticals$59.29 million10.27$-66,890,000.00($0.40)-8.95

Alexion Pharmaceuticals has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Rigel Pharmaceuticals on 10 of the 15 factors compared between the two stocks.


Rigel Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.71-0.2%$147.24 billion$23.36 billion20.62Insider Selling
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.87-1.6%$84.19 billion$22.45 billion68.94Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.39-0.8%$56.78 billion$4.16 billion27.70Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.60-1.6%$53.84 billion$7.86 billion18.37Analyst Report
Biogen logo
BIIB
Biogen
1.9$270.31-0.0%$41.18 billion$14.38 billion8.95Upcoming Earnings
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$163.68-3.8%$35.98 billion$4.99 billion38.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Seagen logo
SGEN
Seagen
1.7$145.50-2.8%$26.38 billion$916.71 million57.28Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$130.04-0.4%$21.99 billion$876.29 million-58.84
Incyte logo
INCY
Incyte
1.7$82.68-0.6%$18.18 billion$2.16 billion-52.66
Novavax logo
NVAX
Novavax
1.2$227.35-11.1%$16.79 billion$18.66 million-43.55
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.88-0.1%$16.29 billion$219.75 million-17.74
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.40-0.8%$14.44 billion$1.70 billion18.17News Coverage
Repligen logo
RGEN
Repligen
1.5$213.30-0.1%$11.68 billion$270.24 million260.12
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.58-1.6%$9.13 billion$788.10 million103.85Analyst Upgrade
Increase in Short Interest
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73-1.0%$9.07 billion$1.45 billion19.27Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$23.59-1.5%$7.36 billion$967.78 million49.15
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.41-0.5%$6.65 billion$195.99 million290.06Insider Selling
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.31-5.3%$2.05 billion$638.60 million-10.50
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$23.60-4.0%$1.52 billion$68.46 million-67.43Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Curis logo
CRIS
Curis
1.3$11.49-6.3%$1.05 billion$10 million-14.01Increase in Short Interest
MannKind logo
MNKD
MannKind
1.4$4.18-2.9%$1.04 billion$63.04 million-19.90Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$23.55-0.0%$932.93 million$3.57 million-10.56Analyst Upgrade
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.36-8.8%$812.29 millionN/A0.00Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40News Coverage
Geron logo
GERN
Geron
1.4$1.47-2.7%$468.24 million$460,000.00-4.20Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$460.07 million$17.46 million-1.90
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
News Coverage
XOMA logo
XOMA
XOMA
1.3$37.50-0.9%$422.18 million$18.37 million-33.78Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.12-7.8%$391.02 million$36.63 million-4.85Gap Up
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.